An ongoing open-label, phase 2 trial of RP2 Or RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma

被引：0
|
作者：
Elez, E. [1 ,2 ]
Shepard, D. [3 ]
Smolenschi, C. [4 ]
Bekaii-Saab, T. [5 ]
Jac, J. [6 ]
机构：
[1] Vall dHebron Univ Hosp, Barcelona, Spain
[2] Vall dHebron Inst Oncol, Barcelona, Spain
[3] Cleveland Clin, Cleveland, OH 44106 USA
[4] Gustave Roussy, Dept Med Oncol, Villejuif, France
[5] Mayo Clin, Phoenix, AZ USA
[6] Replimune Inc, Woburn, MA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.04.114
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-58
引用
收藏
页码：S34 / S35
页数：2
相关论文
共 50 条
  • [21] Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer
    Michael, Michael
    Gibbs, Peter
    Smith, Robert
    Godwood, Alex
    Oliver, Stuart
    Tebbutt, Niall
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (03) : 253 - 261
  • [22] Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer
    Michael Michael
    Peter Gibbs
    Robert Smith
    Alex Godwood
    Stuart Oliver
    Niall Tebbutt
    Investigational New Drugs, 2009, 27 : 253 - 261
  • [23] Safety, efficacy, and biomarker results from an open-label, multicenter, phase 1 study of RP2 alone or combined with nivolumab in a cohort of patients with uveal melanoma
    Sacco, Joseph J.
    Harrington, Kevin Joseph
    Olsson-Brown, Anna
    Chan, Tze Y.
    Nenclares, Pablo
    Leslie, Isla
    Bommareddy, Praveen
    Kalbasi, Alireza
    Xie, Ben
    Mishal, Moran
    Cohan, David Michael
    Skolariki, Aglaia
    Middleton, Mark R.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
    Kerr, Rachel S.
    Love, Sharon
    Segelov, Eva
    Johnstone, Elaine
    Falcon, Beverly
    Hewett, Peter
    Weaver, Andrew
    Church, David
    Scudder, Claire
    Pearson, Sarah
    Julier, Patrick
    Pezzella, Francesco
    Tomlinson, Ian
    Domingo, Enric
    Kerr, David J.
    LANCET ONCOLOGY, 2016, 17 (11): : 1543 - 1557
  • [25] Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A for Nonrandomized, Open-label, Phase II Trial
    Xu, Jianming
    Shen, Jie
    Gu, Shanzhi
    Zhang, Yun
    Wu, Lihua
    Wu, Jian
    Shao, Guoliang
    Zhang, Yanqiao
    Xu, Li
    Yin, Tao
    Liu, Jingfeng
    Ren, Zhenggang
    Xiong, Jianping
    Mao, Xianhai
    Zhang, Ling
    Yang, Jiayin
    Li, Lequn
    Chen, Xiaoming
    Wang, Zhiming
    Gu, Kangsheng
    Chen, Xi
    Pan, Zhanyu
    Ma, Kuansheng
    Zhou, Xinmin
    Yu, Zujiang
    Li, Enxiao
    Yin, Guowen
    Zhang, Xiao
    Wang, Shuni
    Wang, Quanren
    CLINICAL CANCER RESEARCH, 2021, 27 (04) : 1003 - 1011
  • [26] A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS]
    Haydon, A. M.
    Alamgeer, M.
    Brungs, D.
    Collichio, F.
    Khushalani, N. I.
    Colevas, A. D.
    Rischin, D.
    Kudchadkar, R.
    Chai-Ho, W.
    Daniels, G.
    Lutzky, J.
    Lee, J. H.
    Bowyer, S.
    Migden, M. R.
    Sheladia, P.
    Bommareddy, P. K.
    He, S.
    Andreu-Vieyra, C.
    Fury, M. G.
    Hill, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S904 - S904
  • [27] Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
    Motzer, Robert J.
    Hutson, Thomas E.
    Glen, Hilary
    Michaelson, M. Dror
    Molina, Ana
    Eisen, Timothy
    Jassem, Jacek
    Zolnierek, Jakub
    Pablo Maroto, Jose
    Mellado, Begona
    Melichar, Bohuslav
    Tomasek, Jiri
    Kremer, Alton
    Kim, Han-Joo
    Wood, Karen
    Dutcus, Corina
    Larkin, James
    LANCET ONCOLOGY, 2015, 16 (15): : 1473 - 1482
  • [28] Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial
    Ducreux, Michel
    Malka, David
    Mendiboure, Jean
    Etienne, Pierre-Luc
    Texereau, Patrick
    Auby, Dominique
    Rougier, Philippe
    Gasmi, Mohamed
    Castaing, Marine
    Abbas, Moncef
    Michel, Pierre
    Gargot, Dany
    Azzedine, Ahmed
    Lombard-Bohas, Catherine
    Geoffroy, Patrick
    Denis, Bernard
    Pignon, Jean-Pierre
    Bedenne, Laurent
    Bouche, Olivier
    LANCET ONCOLOGY, 2011, 12 (11): : 1032 - 1044
  • [29] Camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (RESCUE): An open-label, multicenter, phase II trial
    Xu, J.
    Shen, J.
    Gu, S.
    Zhang, Y.
    Wu, L.
    Wu, J.
    Shao, G.
    Zhang, Y.
    Xu, L.
    Yin, T.
    Liu, J.
    Ren, Z.
    Xiong, J.
    Mao, X.
    Zhang, L.
    Yang, J.
    Li, L.
    Chen, X.
    Wang, Z.
    Wang, Q.
    ANNALS OF ONCOLOGY, 2020, 31 : S689 - S689
  • [30] Update on overall survival (OS) of RESCUE: An open-label, phase 2 trial of camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (HCC).
    Zhang, Yun
    Xu, Jianming
    Shen, Jie
    Gu, Shanzhi
    Wu, Lihua
    Wu, Jian
    Shao, Guoliang
    Zhang, Yanqiao
    Xu, Li
    Yin, Tao
    Liu, Jingfeng
    Ren, Zhenggang
    Xiong, Jianping
    Mao, Xianhai
    Zhang, Ling
    Yang, Jiayin
    Li, Lequn
    Chen, Xiaoming
    Wang, Zhiming
    Wang, Quanren
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345